Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Measles Virus-Based Treatments Trigger a Pro-inflammatory Cascade and a Distinctive Immunopeptidome in Glioblastoma.

Rajaraman S, Canjuga D, Ghosh M, Codrea MC, Sieger R, Wedekink F, Tatagiba M, Koch M, Lauer UM, Nahnsen S, Rammensee HG, Mühlebach MD, Stevanovic S, Tabatabai G.

Mol Ther Oncolytics. 2018 Dec 31;12:147-161. doi: 10.1016/j.omto.2018.12.010. eCollection 2019 Mar 29.

2.

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastases in Solid Organ Graft Recipients: First Experience.

Horvath P, Yurttas C, Struller F, Bösmüller H, Lauer UM, Nadalin S, Königsrainer A, Reymond MA.

Ann Transplant. 2019 Jan 15;24:30-35. doi: 10.12659/AOT.911905.

3.

6- and 8-Prenylnaringenin, Novel Natural Histone Deacetylase Inhibitors Found in Hops, Exert Antitumor Activity on Melanoma Cells.

Venturelli S, Niessner H, Sinnberg T, Berger A, Burkard M, Urmann C, Donaubauer K, Böcker A, Leischner C, Riepl H, Frank J, Lauer UM, Garbe C, Busch C.

Cell Physiol Biochem. 2018;51(2):543-556. doi: 10.1159/000495275. Epub 2018 Nov 20.

4.

Three-dimensional tumor cell cultures employed in virotherapy research.

Kloker LD, Yurttas C, Lauer UM.

Oncolytic Virother. 2018 Sep 5;7:79-93. doi: 10.2147/OV.S165479. eCollection 2018. Review.

5.

Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.

Grottenthaler JM, Werner CR, Steurer M, Spengler U, Berg T, Engelmann C, Wedemeyer H, von Hahn T, Stremmel W, Pathil A, Seybold U, Schott E, Blessin U, Sarrazin C, Welker MW, Harrer E, Scholten S, Hinterleitner C, Lauer UM, Malek NP, Berg CP.

PLoS One. 2018 Jun 6;13(6):e0197544. doi: 10.1371/journal.pone.0197544. eCollection 2018.

6.

Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis.

Lauer UM, Schell M, Beil J, Berchtold S, Koppenhöfer U, Glatzle J, Königsrainer A, Möhle R, Nann D, Fend F, Pfannenberg C, Bitzer M, Malek NP.

Clin Cancer Res. 2018 Sep 15;24(18):4388-4398. doi: 10.1158/1078-0432.CCR-18-0244. Epub 2018 May 17.

PMID:
29773661
7.

The Oral Bioavailability of 8-Prenylnaringenin from Hops (Humulus Lupulus L.) in Healthy Women and Men is Significantly Higher than that of its Positional Isomer 6-Prenylnaringenin in a Randomized Crossover Trial.

Calvo-Castro LA, Burkard M, Sus N, Scheubeck G, Leischner C, Lauer UM, Bosy-Westphal A, Hund V, Busch C, Venturelli S, Frank J.

Mol Nutr Food Res. 2018 Apr;62(7):e1700838. doi: 10.1002/mnfr.201700838. Epub 2018 Mar 1.

PMID:
29363261
8.

Durch Pembrolizumab verursachte Hepatitis: Diagnose und Behandlung.

Forschner A, Schraml C, Pierchalla K, Weide B, Eigentler TK, Lauer UM, Garbe C.

J Dtsch Dermatol Ges. 2017 Sep;15(9):933-935. doi: 10.1111/ddg.13037_g. No abstract available.

PMID:
28872244
9.

Pembrolizumab-induced hepatitis: diagnosis and treatment.

Forschner A, Schraml C, Pierchalla K, Weide B, Eigentler TK, Lauer UM, Garbe C.

J Dtsch Dermatol Ges. 2017 Sep;15(9):933-935. doi: 10.1111/ddg.13037. No abstract available.

PMID:
28872228
10.

Virotherapy Research in Germany: From Engineering to Translation.

Ungerechts G, Engeland CE, Buchholz CJ, Eberle J, Fechner H, Geletneky K, Holm PS, Kreppel F, Kühnel F, Lang KS, Leber MF, Marchini A, Moehler M, Mühlebach MD, Rommelaere J, Springfeld C, Lauer UM, Nettelbeck DM.

Hum Gene Ther. 2017 Oct;28(10):800-819. doi: 10.1089/hum.2017.138. Review.

PMID:
28870120
11.

Chemovirotherapy of Pancreatic Adenocarcinoma by Combining Oncolytic Vaccinia Virus GLV-1h68 with nab-Paclitaxel Plus Gemcitabine.

Binz E, Berchtold S, Beil J, Schell M, Geisler C, Smirnow I, Lauer UM.

Mol Ther Oncolytics. 2017 Apr 19;6:10-21. doi: 10.1016/j.omto.2017.04.001. eCollection 2017 Sep 15.

12.

[Varicella gastritis under immunosuppression : Case report of a woman after lung transplantation due to granulomatosis with polyangiitis].

Saman S, Henes JC, Niepel D, Bosmüller H, Werner CR, Lauer UM, Malek NP, Xenitidis T.

Internist (Berl). 2017 Aug;58(8):855-858. doi: 10.1007/s00108-017-0231-2. German.

PMID:
28405696
13.

Dietary flavonoids and modulation of natural killer cells: implications in malignant and viral diseases.

Burkard M, Leischner C, Lauer UM, Busch C, Venturelli S, Frank J.

J Nutr Biochem. 2017 Aug;46:1-12. doi: 10.1016/j.jnutbio.2017.01.006. Epub 2017 Jan 24. Review.

PMID:
28182964
14.

Impact of transjugular intrahepatic portosystemic shunt implantation on liver perfusion measured by volume perfusion CT.

Preibsch H, Spira D, Thaiss WM, Syha R, Nikolaou K, Ketelsen D, Lauer UM, Horger M.

Acta Radiol. 2017 Oct;58(10):1167-1173. doi: 10.1177/0284185116685922. Epub 2017 Jan 13.

PMID:
28084812
15.

Hepatitis C "true" late relapse beyond 48weeks of sustained virologic response after direct acting antiviral therapy.

Klag T, Dietz J, Werner CR, Schwarz JM, Lauer UM, Beck R, Malek NP, Sarrazin C, Berg CP.

J Hepatol. 2017 Apr;66(4):862-863. doi: 10.1016/j.jhep.2017.01.002. Epub 2017 Jan 9. No abstract available.

PMID:
28082147
16.

Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus.

Ellerhoff TP, Berchtold S, Venturelli S, Burkard M, Smirnow I, Wulff T, Lauer UM.

Int J Oncol. 2016 Nov;49(5):1931-1944. doi: 10.3892/ijo.2016.3675. Epub 2016 Aug 31.

PMID:
27601235
17.

Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12.

Werner CR, Schwarz JM, Egetemeyr DP, Beck R, Malek NP, Lauer UM, Berg CP.

World J Gastroenterol. 2016 Sep 21;22(35):8050-9. doi: 10.3748/wjg.v22.i35.8050.

18.

Prenylated chalcones and flavonoids for the prevention and treatment of cancer.

Venturelli S, Burkard M, Biendl M, Lauer UM, Frank J, Busch C.

Nutrition. 2016 Nov-Dec;32(11-12):1171-8. doi: 10.1016/j.nut.2016.03.020. Epub 2016 Apr 8. Review.

PMID:
27238957
19.

Nutritional immunology: function of natural killer cells and their modulation by resveratrol for cancer prevention and treatment.

Leischner C, Burkard M, Pfeiffer MM, Lauer UM, Busch C, Venturelli S.

Nutr J. 2016 May 4;15(1):47. doi: 10.1186/s12937-016-0167-8. Review.

20.

Allelochemicals of the phenoxazinone class act at physiologically relevant concentrations.

Venturelli S, Petersen S, Langenecker T, Weigel D, Lauer UM, Becker C.

Plant Signal Behav. 2016 May 3;11(5):e1176818. doi: 10.1080/15592324.2016.1176818.

21.

Three-dimensional C-arm CT-guided transjugular intrahepatic portosystemic shunt placement: Feasibility, technical success and procedural time.

Ketelsen D, Groezinger G, Maurer M, Lauer UM, Grosse U, Horger M, Nikolaou K, Syha R.

Eur Radiol. 2016 Dec;26(12):4277-4283. Epub 2016 Apr 5.

PMID:
27048535
22.

Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.

Bitzer M, Horger M, Giannini EG, Ganten TM, Wörns MA, Siveke JT, Dollinger MM, Gerken G, Scheulen ME, Wege H, Zagonel V, Cillo U, Trevisani F, Santoro A, Montesarchio V, Malek NP, Holzapfel J, Herz T, Ammendola AS, Pegoraro S, Hauns B, Mais A, Lauer UM, Henning SW, Hentsch B.

J Hepatol. 2016 Aug;65(2):280-8. doi: 10.1016/j.jhep.2016.02.043. Epub 2016 Mar 4.

PMID:
26952006
23.

Plants Release Precursors of Histone Deacetylase Inhibitors to Suppress Growth of Competitors.

Venturelli S, Belz RG, Kämper A, Berger A, von Horn K, Wegner A, Böcker A, Zabulon G, Langenecker T, Kohlbacher O, Barneche F, Weigel D, Lauer UM, Bitzer M, Becker C.

Plant Cell. 2015 Nov;27(11):3175-89. doi: 10.1105/tpc.15.00585. Epub 2015 Nov 3.

24.

Epigenetic activities of flavonoids in the prevention and treatment of cancer.

Busch C, Burkard M, Leischner C, Lauer UM, Frank J, Venturelli S.

Clin Epigenetics. 2015 Jul 10;7:64. doi: 10.1186/s13148-015-0095-z. eCollection 2015.

25.

Epidemiology and Genotyping of Patients with Chronic Hepatitis B: Genotype Shifting Observed in Patients from Central Europe.

Bissinger AL, Fehrle C, Werner CR, Lauer UM, Malek NP, Berg CP.

Pol J Microbiol. 2015;64(1):15-21.

26.

Anti-proliferative activity of hop-derived prenylflavonoids against human cancer cell lines.

Busch C, Noor S, Leischner C, Burkard M, Lauer UM, Venturelli S.

Wien Med Wochenschr. 2015 Jun;165(11-12):258-61. doi: 10.1007/s10354-015-0355-8. Epub 2015 Apr 30. Review.

PMID:
25925225
27.

First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort.

Werner CR, Franz C, Egetemeyr DP, Beck R, Malek NP, Lauer UM, Berg CP.

Virol J. 2015 Mar 3;12:37. doi: 10.1186/s12985-015-0261-0.

28.

Chemovirotherapy: combining chemotherapeutic treatment with oncolytic virotherapy.

Binz E, Lauer UM.

Oncolytic Virother. 2015 Feb 23;4:39-48. doi: 10.2147/OV.S54780. eCollection 2015. Review.

29.

Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma.

Ruf B, Berchtold S, Venturelli S, Burkard M, Smirnow I, Prenzel T, Henning SW, Lauer UM.

Mol Ther Oncolytics. 2015 Oct 7;2:15019. doi: 10.1038/mto.2015.19. eCollection 2015.

30.

Assessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly"?

Ruf B, Lauer UM.

Mol Ther Oncolytics. 2015 Nov 4;2:15018. doi: 10.1038/mto.2015.18. eCollection 2015. Review.

31.

Epigenetic impacts of ascorbate on human metastatic melanoma cells.

Venturelli S, Sinnberg TW, Berger A, Noor S, Levesque MP, Böcker A, Niessner H, Lauer UM, Bitzer M, Garbe C, Busch C.

Front Oncol. 2014 Aug 25;4:227. doi: 10.3389/fonc.2014.00227. eCollection 2014.

32.

[Sometimes a liver can cause you headaches].

Müller NF, Lauer UM, Horger M, Malek NP, Berg CP.

Dtsch Med Wochenschr. 2014 Jun;139(25-26):1352. doi: 10.1055/s-0034-1370149. Epub 2014 Jun 25. German.

33.

Pulsed versus continuous application of the prodrug 5-fluorocytosine to enhance the oncolytic effectiveness of a measles vaccine virus armed with a suicide gene.

Yurttas C, Berchtold S, Malek NP, Bitzer M, Lauer UM.

Hum Gene Ther Clin Dev. 2014 Jun;25(2):85-96. doi: 10.1089/humc.2013.127.

PMID:
24933569
34.

Efficacy and safety of telaprevir (TVR) triple therapy in a 'real-life' cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment.

Werner CR, Franz C, Egetemeyr DP, Janke-Maier P, Malek NP, Lauer UM, Berg CP.

J Viral Hepat. 2014 May;21(5):333-40. doi: 10.1111/jvh.12145. Epub 2013 Aug 5.

PMID:
24716636
35.

Attenuated and protease-profile modified sendai virus vectors as a new tool for virotherapy of solid tumors.

Zimmermann M, Armeanu-Ebinger S, Bossow S, Lampe J, Smirnow I, Schenk A, Lange S, Weiss TS, Neubert W, Lauer UM, Bitzer M.

PLoS One. 2014 Mar 5;9(3):e90508. doi: 10.1371/journal.pone.0090508. eCollection 2014.

36.

[An unexpected cause of progressive hepatopathy - Case 2/2014].

Federmann B, Lauer UM, Haen S, Kilias A, Artunc F, Riessen R, Fend F, Haap M.

Dtsch Med Wochenschr. 2014 Feb;139(8):378. doi: 10.1055/s-0033-1360047. Epub 2014 Feb 11. German. No abstract available.

37.

Treatment of recurrent genotype 1 hepatitis C post-liver transplantation: single center experience with telaprevir-based triple therapy.

Werner CR, Egetemeyr DP, Nadalin S, Königsrainer A, Malek NP, Lauer UM, Berg CP.

Z Gastroenterol. 2014 Jan;52(1):27-34. doi: 10.1055/s-0033-1356345. Epub 2014 Jan 13.

PMID:
24420796
38.

Feasibility of telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: SVR 24 results.

Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP.

PLoS One. 2013 Nov 12;8(11):e80528. doi: 10.1371/journal.pone.0080528. eCollection 2013.

39.

Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells.

Venturelli S, Berger A, Böcker A, Busch C, Weiland T, Noor S, Leischner C, Schleicher S, Mayer M, Weiss TS, Bischoff SC, Lauer UM, Bitzer M.

PLoS One. 2013 Aug 30;8(8):e73097. doi: 10.1371/journal.pone.0073097. eCollection 2013. Erratum in: PLoS One. 2013;8(9). doi:10.1371/annotation/5b9a8614-1009-40ca-b90b-db817fe445c9.

40.

Optical detection and virotherapy of live metastatic tumor cells in body fluids with vaccinia strains.

Wang H, Chen NG, Minev BR, Zimmermann M, Aguilar RJ, Zhang Q, Sturm JB, Fend F, Yu YA, Cappello J, Lauer UM, Szalay AA.

PLoS One. 2013 Sep 3;8(9):e71105. doi: 10.1371/journal.pone.0071105. eCollection 2013.

41.

Differential induction of apoptosis and senescence by the DNA methyltransferase inhibitors 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumor cells.

Venturelli S, Berger A, Weiland T, Essmann F, Waibel M, Nuebling T, Häcker S, Schenk M, Schulze-Osthoff K, Salih HR, Fulda S, Sipos B, Johnstone RW, Lauer UM, Bitzer M.

Mol Cancer Ther. 2013 Oct;12(10):2226-36. doi: 10.1158/1535-7163.MCT-13-0137. Epub 2013 Aug 7.

42.

Enhanced killing of therapy-induced senescent tumor cells by oncolytic measles vaccine viruses.

Weiland T, Lampe J, Essmann F, Venturelli S, Berger A, Bossow S, Berchtold S, Schulze-Osthoff K, Lauer UM, Bitzer M.

Int J Cancer. 2014 Jan 1;134(1):235-43. doi: 10.1002/ijc.28350. Epub 2013 Aug 7.

43.

An armed oncolytic measles vaccine virus eliminates human hepatoma cells independently of apoptosis.

Lampe J, Bossow S, Weiland T, Smirnow I, Lehmann R, Neubert W, Bitzer M, Lauer UM.

Gene Ther. 2013 Nov;20(11):1033-41. doi: 10.1038/gt.2013.28. Epub 2013 May 30.

PMID:
23719065
44.

Intrahepatic application of suicide gene-armed measles virotherapeutics: a safety study in transgenic mice and rhesus macaques.

Völker I, Bach P, Coulibaly C, Plesker R, Abel T, Seifried J, Heidmeier S, Mühlebach MD, Lauer UM, Buchholz CJ.

Hum Gene Ther Clin Dev. 2013 Mar;24(1):11-22. doi: 10.1089/humc.2012.242. Epub 2013 Apr 3.

PMID:
23692379
45.

Enhanced killing of ovarian carcinoma using oncolytic measles vaccine virus armed with a yeast cytosine deaminase and uracil phosphoribosyltransferase.

Hartkopf AD, Bossow S, Lampe J, Zimmermann M, Taran FA, Wallwiener D, Fehm T, Bitzer M, Lauer UM.

Gynecol Oncol. 2013 Aug;130(2):362-8. doi: 10.1016/j.ygyno.2013.05.004. Epub 2013 May 12.

PMID:
23676551
46.

Primary resistance phenomena to oncolytic measles vaccine viruses.

Noll M, Berchtold S, Lampe J, Malek NP, Bitzer M, Lauer UM.

Int J Oncol. 2013 Jul;43(1):103-12. doi: 10.3892/ijo.2013.1914. Epub 2013 Apr 23.

PMID:
23612727
47.

A novel armed oncolytic measles vaccine virus for the treatment of cholangiocarcinoma.

Lange S, Lampe J, Bossow S, Zimmermann M, Neubert W, Bitzer M, Lauer UM.

Hum Gene Ther. 2013 May;24(5):554-64. doi: 10.1089/hum.2012.136.

48.

Innate immune defense defines susceptibility of sarcoma cells to measles vaccine virus-based oncolysis.

Berchtold S, Lampe J, Weiland T, Smirnow I, Schleicher S, Handgretinger R, Kopp HG, Reiser J, Stubenrauch F, Mayer N, Malek NP, Bitzer M, Lauer UM.

J Virol. 2013 Mar;87(6):3484-501. doi: 10.1128/JVI.02106-12. Epub 2013 Jan 9.

49.

Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus.

Bach P, Abel T, Hoffmann C, Gal Z, Braun G, Voelker I, Ball CR, Johnston IC, Lauer UM, Herold-Mende C, Mühlebach MD, Glimm H, Buchholz CJ.

Cancer Res. 2013 Jan 15;73(2):865-74. doi: 10.1158/0008-5472.CAN-12-2221. Epub 2013 Jan 4.

50.

Selective protection of human liver tissue in TNF-targeting of cancers of the liver by transient depletion of adenosine triphosphate.

Weiland T, Klein K, Zimmermann M, Speicher T, Venturelli S, Berger A, Bantel H, Königsrainer A, Schenk M, Weiss TS, Wendel A, Schwab M, Bitzer M, Lauer UM.

PLoS One. 2012;7(12):e52496. doi: 10.1371/journal.pone.0052496. Epub 2012 Dec 18.

Supplemental Content

Loading ...
Support Center